Simcere Pharmaceutical Group
http://en.simcere.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Simcere Pharmaceutical Group
Local Generics Win Big In China's Latest National Tender
Only four multinationals, including Pfizer, had to make deep cuts to the prices of their off-patent drugs to outbid local generic competitors in China’s seventh round of centralized volume-based procurement. Among the foreign firms that lost out in the bidding, Eisai looks set to be dealt the heaviest blow in terms of market share.
Junshi’s COVID Antiviral Superior To Paxlovid? Some Caveats Unveiled
Unexpected protocol changes and a single-blind design for a Phase III head-to-head trial seem to have played to the advantage of Junshi’s oral derivative of Gilead’s antiviral remdesivir in COVID-19.
Homegrown China Oral Antiviral Shows Early Promise
Junshi’s oral antiviral shows signs of effectiveness in treating patients with mild COVID-19 symptoms but more data are needed, caution researchers.
China’s Home-Grown Oral COVID Antiviral Eyes Wider Population
Simcere is weighing options for SIM0417 in a Phase I trial in China as the first major domestically-developed potential rival to Pfizer’s oral COVID-19 antiviral Paxlovid. The study is likely to include wider patient groups ranging from those without symptoms to severe patients.
Company Information
- Industry
-
Pharmaceuticals
- Generic Drugs
- OTC, Consumer
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
- Other Names / Subsidiaries
-
- Jilin Boda Pharmaceutical Co., Ltd.
- ChinaVax
- Master Luck Corporation Limited
- Jiangsu Simcere Pharmaceutical R&D Co., Ltd.
- Jiangsu Yanshen Biological Technology Stock Co., Ltd.
- Nanjing Tung Chit Pharmaceutical Co., Ltd.
- Shandong Simcere Medgenn Bio-Pharmaceutical Co. Ltd.
- Wuhu Zhong Ren Pharmaceutical Co. Ltd.
- Xiangao Investment Company Ltd.
- Yantai Medgenn Co. Ltd.
- Jiangsu Simcere Pharmaceutical Co., Ltd.